Canaan and Alpha Wave co-lead EUR 45 million Series B financing round in Acesion Pharma

Mazanti Transactions has advised US-based investors Canaan XII L.P. and Alpha Wave Ventures II, L.P in connection with the investment in Acesion Pharma ApS. The EUR 45 million oversubscribed series B financing round was co-led by Canaan and Alpha Wave with participation by RMG-KB BioAccess Fund L.P., as well as existing investor Novo Holdings A/S.

Acesion Pharma is a Danish biotech company redefining treatment for patients suffering from atrial fibrillation which is the most common cardiac arrhythmia forecast to affect 25 million people in the US and EU by 2030. Existing drug therapies for AF are associated with the risk of serious cardiac effects, resulting in a great need for safer drugs. With AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of atrial fibrillation, Acesion Pharma is aiming to develop a safer alternative, and the financing will be used to advance the clinical development hereof.

Canaan is an early-stage venture capital firm with USD 6.8 billion under management. It invests in entrepreneurs with visionary ideas and partners with the next generation of technology and healthcare companies that will transform how we live, work, and thrive.

Alpha Wave is a global investment company and its flagship global venture and growth fund, Alpha Wave Ventures, aims to invest in best-in-class venture and growth-stage companies.

Mazanti Transactions advised Canaan and Alpha Wave on all aspects of the investment in Acesion Pharma.

Read more here and in Børsen here (in Danish).